共 50 条
- [21] Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials[J]. ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)Malattia, ClaraRuperto, NicolinoPederzoli, SilviaPalmisani, ElenaPistorio, AngelaWouters, CarineDolezalova, PavlaFlato, BeritGaray, StellaGiancane, GabriellaWells, ChrisDouglass, WendyBrunner, Hermine I.De Benedetti, FabrizioRavelli, Angelo
- [22] Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials[J]. Arthritis Research & Therapy, 22Clara MalattiaNicolino RupertoSilvia PederzoliElena PalmisaniAngela PistorioCarine WoutersPavla DolezalovaBerit FlatoStella GarayGabriella GiancaneChris WellsWendy DouglassHermine I. BrunnerFabrizio De BenedettiAngelo Ravelli
- [23] Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials[J]. BMC Musculoskeletal Disorders, 22Jin Kyun ParkSe Han AhnKichul ShinYun Jong LeeYeong Wook SongEun Bong Lee
- [24] Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials[J]. BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)Park, Jin KyunAhn, Se HanShin, KichulLee, Yun JongSong, Yeong WookLee, Eun Bong
- [25] Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72Mysler, EduardoTanaka, YoshiyaKavanaugh, ArthurAletaha, DanielTaylor, PeterSong, In-HoShaw, TimSong, YannaDeMasi, RyanAli, MiraFleischmann, Roy
- [26] IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 566 - 567Mysler, E.Tanaka, Y.Kavanaugh, A.Aletaha, D.Taylor, P. C.Song, I. H.Shaw, T.Song, Y.Demasi, R.Ali, M.Fleischmann, R.
- [27] PREDICTIVE FACTORS FOR REMISSION ACHIEVEMENT BY TOCILIZUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER INADEQUATE RESPONSE TO METHOTREXATE: A POST HOC ANALYSIS OF THE SURPRISE STUDY[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 714 - 715Kato, MasaruKaneko, YukoTanaka, YoshiyaInoo, MasayukiKobayashi-Haraoka, HitomiAmano, KoichiMiyata, MasayukiMurakawa, YohkoYasuoka, HidekataHirata, ShintaroNagasawa, HayatoTanaka, EiichiMiyasaka, NobuyukiYamanaka, HisashiYamamoto, KazuhikoYokota, IsaoAtsumi, TatsuyaTakeuchi, Tsutomu
- [28] Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71de la Vega, MariaGuerra Bautista, GenerosoXavier, Ricardo MachadoPacheco-Tena, CesarSolano, GastonPedersen, RonaldBorlenghi, CecilaSantana, KarinaVlahos, Bonnie
- [29] Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67Wang, XinKavanaugh, Arthurvan der Heijde, DesireeDougados, MaximeFlorentinus, StefanLi, YihanSainsbury, IainSmolen, Josef S.
- [30] EARLY PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES WITH ABT-494 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE OR TUMOR NECROSIS FACTOR INHIBITORS: POST-HOC ANALYSIS OF PHASE 2 RANDOMIZED CONTROLLED TRIALS[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 855 - 855Strand, V.Tundia, N.Song, I. H.Meerwein, S.Lin, J.Chen, N.Friedman, A.